Search results for "IMMUNOLOGY"

showing 10 items of 9651 documents

Pharmacokinetic Study on Adenomatous Prostate Tissue Concentrations of Cef operazone

1989

Cephalosporins do not reach active therapeutical concentrations in the prostatic tissue in patients suffering from chronic bacterial prostatitis. Cefoperazone is an exception. Its efficacy in the trea

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntibioticsCephalosporinProstatitisGastroenterologyPharmacokineticsProstateInternal medicineDrug DiscoverymedicinePharmacology (medical)PharmacologyChemotherapybusiness.industryGeneral Medicinemedicine.diseaseCefoperazoneInfectious Diseasesmedicine.anatomical_structureChronic bacterial prostatitisOncologyImmunologybusinessmedicine.drugChemotherapy
researchProduct

FLT3 as a therapeutic target in AML: still challenging after all these years

2010

Abstract Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML. Over the last years, FLT3 has emerged as a promising molecular target in therapy of AML. Here, we review results of clinical trials and of correlative laboratory studies using small molecule FLT3 tyrosine kinase inhibitors (TKIs) in AML patients. We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy. Finally, for using FLT3 as a molecul…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentImmunologyBiologyBiochemistryTyrosine-kinase inhibitorTargeted therapychemistry.chemical_compoundfluids and secretionshemic and lymphatic diseasesInternal medicinemedicineHumansProtein Kinase InhibitorsQuizartinibHematologyMyeloid leukemiaCancerhemic and immune systemsCell BiologyHematologymedicine.diseaseLeukemia Myeloid Acutefms-Like Tyrosine Kinase 3chemistryDrug Resistance Neoplasmembryonic structuresCancer researchTyrosine kinaseCrenolanibBlood
researchProduct

Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.

1989

Recombinant DNA technology has been central in answering some of the most relevant questions in the research of regulation of the functional status of hematopoietic progenitor cells and their progeny. This leading article will focus on recent results that have emerged from studies utilizing recombinant molecules that control hematopoietic blood cell development and activation. The following features will be detailed: The molecular and biological characteristics and biochemistry of hematopoietic growth factors, synergizing factors and releasing factors, their role in the regulation of hematopoiesis and activation of normal and leukemic cells, their cellular sources, and regulation of product…

medicine.medical_specialtymedicine.medical_treatmentBiologylaw.inventionBlood celllawInternal medicinemedicineAnimalsHumansProgenitor cellGrowth SubstancesCells CulturedHematologyCell growthGrowth factorHematologyGeneral MedicineHematopoietic Stem CellsIn vitroCell biologyHematopoiesisHaematopoiesismedicine.anatomical_structureImmunologyRecombinant DNAPeptidesBlut
researchProduct

Infliximab and ulcerative colitis

2006

Expert Opin Biol Ther. 2006 Apr;6(4):401-8. Infliximab and ulcerative colitis. Cottone M, Mocciaro F, Modesto I. Università di Palermo, Istituto di Medicina Generale e Pneumologia, Via Trabucco 180, Palermo, Italy. dickens@tin.it Tumour necrosis factor (TNF)-alpha is an inflammatory cytokine that plays a main role in the inflammatory process underlying inflammatory bowel disease (IBD). Despite the fact that the cytokine profiles associated with ulcerative colitis (UC) and Crohn's disease (CD) are classically considered different (a Th2 pattern in UC and a Th1 pattern in CD), there are several evidences in vitro and in vivo that TNF-alpha has an important role in UC. For this reason, inflixi…

medicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryInflammatory bowel diseaseGastroenterologyGastrointestinal AgentsInternal medicineDrug Discoverymedicineinfliximab. ulcerative colitisHumansColitisPharmacologyGastrointestinal agentbusiness.industryAntibodies MonoclonalPouchitismedicine.diseaseUlcerative colitisInfliximabInfliximabCytokineImmunologyColitis UlcerativeTumor necrosis factor alphabusinessmedicine.drugExpert Opinion on Biological Therapy
researchProduct

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Societ…

2005

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs a…

medicine.medical_specialtymedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationNeutropenia03 medical and health sciences0302 clinical medicineAnti-Infective AgentsmedicineHumansTransplantation HomologousInfection controlAntibiotic prophylaxisIntensive care medicineBone Marrow TransplantationInfection Controlbusiness.industryImmunosuppressionHematologyAntibiotic ProphylaxisAntimicrobialmedicine.disease3. Good healthTransplantationOncology030220 oncology & carcinogenesisImmunologyPreventive Medicinebusiness030215 immunologyAnnals of Oncology
researchProduct

Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP.

2008

Important targets for cAMP signalling in the heart are hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels that underlie the depolarizing 'pacemaker' current, I(f). We studied the role of I(f) in mice, in which binding of cAMP to HCN4 channels was abolished by a single amino-acid exchange (R669Q). Homozygous HCN4(R669Q/R669Q) mice die during embryonic development. Prior to E12, homozygous and heterozygous embryos display reduced heart rates and show no or attenuated responses to catecholaminergic stimulation. Adult heterozygous mice display normal heart rates at rest and during exercise. However, following beta-adrenergic stimulation, hearts exhibit pauses and sino-atrial…

medicine.medical_specialtymedicine.medical_treatmentCyclic Nucleotide-Gated Cation ChannelsEmbryonic DevelopmentStimulationMice TransgenicBiologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCardiac pacemakerArticleMiceHeart RatePregnancyInternal medicineHeart ratemedicineCyclic AMPHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAnimalsMyocytes CardiacMolecular BiologyIon channelCells CulturedCatecholaminergicGeneral Immunology and MicrobiologyGeneral NeuroscienceEmbryogenesisDepolarizationEmbryoHeartMice Inbred C57BLEndocrinologyMutationFemaleThe EMBO journal
researchProduct

Polypeptides controlling hematopoietic blood cell development and activation

1989

Colony-stimulating factors (CSFs) have entered the clinical arena. Several investigators have explored, in first clinical phase I studies, different routes of administration to define the optimum biological dose, maximum tolerated dose, toxicity, and pharmacokinetics of these reagents. It has been demonstrated that recombinant human (rh) granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF) can be safely administered over a broad dose range to increase number of circulating granulocytes in man. More recently, GM-CSF and G-CSF have been involved in phase Ib/II studies to assess the granulopoietic responses of patients with granulocytopenia due to various underlying disease states i…

medicine.medical_specialtymedicine.medical_treatmentGranulocyteCyclic neutropeniaColony-Stimulating FactorsBone MarrowInternal medicinemedicineHumansAplastic anemiaChemotherapyHematologybusiness.industryHematologyGeneral MedicineHematopoietic Stem Cellsmedicine.diseaseHematopoiesisGranulocyte colony-stimulating factorHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureImmunologyDrug EvaluationPeptidesbusinessmedicine.drugBlut
researchProduct

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials.

1999

The purpose of this study was to evaluate the clinical usefulness of surrogate markers of the interferon effect (i.e., alanine aminotransferase levels and serum HCV-RNA status) as predictors of long term response, and to identify the optimal schedule of treatment for patients with chronic hepatitis C by means of meta-analysis.Pertinent randomized clinical trials and prospective studies were selected using MEDLINE (1986-1996), a reference list from published articles or reviews. Twenty-six prospective studies reporting data on surrogate markers of interferon response were selected. Thirty-nine trials comparing interferon alpha to no treatment and 25 trials comparing different schedules of in…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusHepacivirusAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyDrug Administration Schedulelaw.inventionFlaviviridaeChronic hepatitisRandomized controlled triallawInternal medicinemedicineHumansInterferon alfaRandomized Controlled Trials as TopicHepatologybiologybusiness.industryGastroenterologyInterferon-alphaAlanine TransaminaseImmunotherapyHepatitis C Chronicbiology.organism_classificationImmunologyRNA Viralbusinessmedicine.drugThe American journal of gastroenterology
researchProduct

Hepatitis C virus infection in hemodialyzed patients.

2007

In spite of our present improved knowledge of the epidemiology and pathways of contamination of the hepatitis C virus (HCV), infection still remains a public health problem. One category of patients who have suffered greatly from the consequences of HCV infection is certainly that of hemodialysis patients. In the past, in fact, their need for transfusions exposed these patients to infection and, as a result, subjects on dialysis for over 15 years are today paying the price for those inevitable transfusions, as the virus and its pathways of contagion were unknown then. However, still today, albeit at a much lower prevalence, even subjects with a shorter dialysis age present a higher prevalen…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPopulationBiomedical EngineeringMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologymedicine.disease_causeAsymptomaticAntiviral AgentsBiomaterials03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineRenal DialysisRisk FactorsInternal medicinemedicineHumanseducationDialysiseducation.field_of_studybusiness.industryRibavirinMortality rateTransfusion ReactionGeneral Medicinemedicine.diseaseHepatitis Cchemistry030220 oncology & carcinogenesisImmunologyHemodialysismedicine.symptombusinessThe International journal of artificial organs
researchProduct

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the G…

2018

Abstract Introduction Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Underlying mechanisms are poorly known and usually multifactorial. Its treatment is not well defined, mostly based in platelet transfusion. Thus, is important to identify new strategies to manage this important post-SCT complication. Romiplostim and Eltrombopag are currently available thrombopoietin receptor agonists (TPO-RAs) that stimulate platelet production. Some studies with very small number of cases have reported their potential efficacy in the allo-SCT setting. For this reason, the aim of our study is to analyze the efficacy and safety of TPO-RAs for s…

medicine.medical_specialtymedicine.medical_treatmentImmunologyEltrombopagHematopoietic stem cell transplantationNeutropeniaBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinePlateletRomiplostimbusiness.industryCell BiologyHematologymedicine.diseaseTransplantationPlatelet transfusionGraft-versus-host diseasechemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drugBlood
researchProduct